Bhavana (Tina) Bhatnagar, DO

Bhavana Bhatnagar, DO, says payer support for social needs, registries, and survivorship care can help patients access therapy and thrive.

Robust survivorship programs exist at some institutions, but needs vary widely from patient to patient, explains Bhavana Bhatnagar, DO.

For Bhavana Bhatnagar, DO, delivering bispecifics and CAR T-cell therapy requires infrastructure, education, SOPs, and experienced academic colleagues.

Institutions need to think more creatively about how they identify and elevate talent, explains Bhavana Bhatnagar, DO.

Bhavana Bhatnagar, DO, who moved from academic to community oncology, shares why stronger academic-community partnerships are essential for patient care.

Bhavana “Tina” Bhatnagar, DO, reflects on AML’s transformation from few treatment options to targeted therapies and efforts to increase access to them.

Bhavana (Tina) Bhatnagar, DO, explains how age, comorbidities, fertility, and individual goals drive personalized treatment decisions in ALL and AML.

A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age populations, explains Tina Bhatnagar, DO.

Bhavana (Tina) Bhatnagar, DO, advocates for AI and diverse clinical trials to bridge equity gaps in precision oncology and value-based care.

Tina Bhatnagar, DO, speaks to the importance of diversity in clinical trials and the need to remove barriers, enroll underrepresented backgrounds, and reflect real-world health conditions.

Bhavana (Tina) Bhatnagar, DO, discusses the transformative role of AI in enhancing patient care at West Virginia University Cancer Institute.

Despite the impact of targeted treatment in oncology, much work remains to bring these therapeutics to all patients, says Bhavana (Tina) Bhatnagar, DO.